Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy
The radiopharmaceutical development and the preclinical/clinical results support the initiation of a first clinical trial to evaluate the therapeutic potential of [<sup>177</sup>Lu]Lu-DOTA-MGS5 in PRRT.
Authors
- Peter Laverman
- Leonhard Gruber (ORCID: https://orcid.org/0000-0003-3351-799X)
- Elisabeth von Guggenberg (ORCID: https://orcid.org/0000-0003-4944-4705)
- Clemens Decristoforo (ORCID: https://orcid.org/0000-0003-0566-4036)
- Taraneh Sadat Zavvar (ORCID: https://orcid.org/0000-0003-4965-5297)
- Lieke Joosten (ORCID: https://orcid.org/0000-0003-4427-8664)
- Irene Johanna Virgolini (ORCID: https://orcid.org/0000-0001-7097-6170)
- Mark Konijnenberg (ORCID: https://orcid.org/0000-0001-5895-8500)
- Martin Kraihammer (ORCID: https://orcid.org/0009-0005-8467-1841)
- Anton Amadeus Hörmann (ORCID: https://orcid.org/0000-0002-0119-3102)
- Gianpaolo di Santo
- Christian Mair (ORCID: https://orcid.org/0000-0001-6549-4951)
- Ariane Kronthaler (ORCID: https://orcid.org/0009-0007-9442-6158)
Institutions
- Innsbruck Medical University (AT)
- Radboud University Nijmegen (NL)
- Universität Innsbruck (AT)
- Erasmus MC (NL)
- University Medical Center (US)
- Radboud University Medical Center (NL)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2024-12-07
- DOI
- https://doi.org/10.1007/s00259-024-06979-1
- Citations
- 6
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 2.32
Funders
- Austrian Science Fund